Please ensure Javascript is enabled for purposes of website accessibility

Why Kadmon Stock Popped Today

By Evan Niu, CFA – Aug 7, 2020 at 5:15PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The developmental biotech reported quarterly results and gave investors updates on its drug pipeline.

What happened

Shares of Kadmon Holdings (KDMN) popped by 11% today after the biotech reported second-quarter earnings. The company also provided updates on its drug pipeline.

So what

Revenue in the second quarter was $448,000, which resulted in an operating loss of $26.9 million. Net loss was $27.7 million, or $0.17 per share. The developmental biotech company said results from a recent drug trial were encouraging.

Scientist with gloved hands using pipette on  a rack of test tubes

Image source: Getty Images.

"Following positive topline results from the primary analysis of the ROCKstar pivotal trial of belumosudil in cGVHD announced in May 2020, we have had an extremely busy and productive quarter," CEO Dr. Harlan Waksal said in a statement. "We are preparing our New Drug Application [NDA] for belumosudil, which remains on track for submission in the fourth quarter of this year."

Now what

Kadmon raised $50 million during the quarter through an at-the-market (ATM) stock offering, which the chief executive said has capitalized the company so that it can proceed through the NDA filing, approval, and launch of belumosudil. Following that capital raise, which helped mitigate operating cash burn of $37.5 million in the first half of 2020, the company finished the second quarter with $169.8 million in cash.

Meanwhile, Kadmon recently commenced a phase 1 clinical trial of a different drug candidate. Dr. Waksal added, "Furthermore, we were pleased to announce this quarter that the first patient was dosed in a Phase 1 clinical trial of KD033, our novel anti-PD-L1/IL-15 immuno-oncology fusion protein, in patients with metastatic or locally advanced solid tumors."

Evan Niu, CFA has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.